title: [Predictive factors of ESBL versus non-ESBL Escherichia coli bacteraemia and influence of resistance on the mortality of the patients].
abstract: OBJECTIVE
  To analyze predictor factors of extended-spectrum betalactamasa (ESBL)-producing E. coli and its repercussion in mortality.
  
  
  METHODS
  Observational and comparative study of a cohort of non-paediatric admitted patients with E. coli bacteraemia (EB).
  
  
  RESULTS
  153 EB (22% ESBL-producing strains). Risk factors associated with ESBLB: previous antibiotic treatment (OR 2.61; 95% CI 1.1-6.19), severity Winston score ≤2 (OR 9.83, 95% CI 3.42-28.26) and health-related acquired infection (OR 5.35; 95% CI 1.57-18.27). Related mortality rate was 21%, being independent risk factors: cancer (OR 4.02; 95% CI 1.08-14.82), high severity of underlying disease (McCabe) (OR 7.69; 95% CI 1.96-30.09) and critical severity of illness at onset (Winston) (OR 48.89; 95% CI 11.58-206.97). Inappropriate empirical therapy was more frequent in EBSL-producing group (67%, p<0.05).
  
  
  CONCLUSIONS
  Previous antibiotic treatment, severity Winston score ≤2 and health-related acquisition are factors associated to ESBL EB. EBSL-producing strains or inadequate treatment were not associated to higher mortality. Factors statistically associated to mortality were cancer, severity of underlying diseases and critical severity of illness at onset.
authors.affiliation: Servicio de Medicina Interna-Infecciosas, Hospital Universitario Virgen de la Arrixaca, El Palmar, Murcia, España.
authors.forename: Ana
authors.initials: A
authors.lastname: García Hernández
authors.forename: Elisa
authors.initials: E
authors.lastname: García-Vázquez
authors.forename: Joaquín
authors.initials: J
authors.lastname: Gómez Gómez
authors.forename: Manuel
authors.initials: M
authors.lastname: Canteras
authors.forename: Alicia
authors.initials: A
authors.lastname: Hernandez-Torres
authors.forename: Joaquín
authors.initials: J
authors.lastname: Ruiz Gómez
mesh_terms: D016470:Bacteremia / Q000188:drug therapy* / Q000401:mortality*; D024881:Drug Resistance, Bacterial; D004926:Escherichia coli / Q000187:drug effects / Q000201:enzymology; D004927:Escherichia coli Infections / Q000188:drug therapy* / Q000401:mortality*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D011446:Prospective Studies; D012189:Retrospective Studies; D001618:beta-Lactamases
chemical_list: D001618:beta-Lactamases